Policy changes Backwork has recorded, newest first. The most recent change on record is from October 14, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
83,427 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| Aug 2, 2026 | Point32Health | Mytesi (crofelemer) Step Therapy | New policy |
| Aug 2, 2026 | Point32Health | Mytesi (crofelemer) | New policy |
| Aug 2, 2026 | Point32Health | Myalept (metreleptin) | New policy |
| Aug 2, 2026 | Point32Health | Montelukast (Singulair) Granules | New policy |
| Aug 2, 2026 | Point32Health | Migraine Medications: Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists and Triptans | New policy |
| Aug 2, 2026 | Point32Health | Metaxalone 800 milligram tablet | New policy |
| Aug 2, 2026 | Point32Health | Medications for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) | New policy |
| Aug 2, 2026 | Point32Health | Medications for the Treatment of Hepatitis C | New policy |
| Aug 2, 2026 | Point32Health | Medications for Dry Eye Disease | New policy |
| Aug 2, 2026 | Point32Health | Mavyret (glecaprevir/pibrentasvir) | New policy |
| Aug 2, 2026 | Point32Health | Mavenclad (cladribine) Tablets | New policy |
| Aug 2, 2026 | Point32Health | Lupkynis (voclosporin) | New policy |
| Aug 2, 2026 | Point32Health | Lupkynis (voclosporin) | New policy |
| Aug 2, 2026 | Point32Health | Lucemyra (lofexidine) Step Therapy | New policy |
| Aug 2, 2026 | Point32Health | Livtencity (maribavir) | New policy |
| Aug 2, 2026 | Point32Health | Livtencity (maribavir) | New policy |
| Aug 2, 2026 | Point32Health | Livmarli (maralixibat) | New policy |
| Aug 2, 2026 | Point32Health | Litfulo (ritlecitinib) | New policy |
| Aug 2, 2026 | Point32Health | Lipodystrophy Agents | New policy |
| Aug 2, 2026 | Point32Health | Lipid Lowering Agents | New policy |
| Aug 2, 2026 | Point32Health | Lidocaine 5% Patches | New policy |
| Aug 2, 2026 | Point32Health | Leqselvi (deuruxolitinib) | New policy |
| Aug 2, 2026 | Point32Health | Kuvan (sapropterin) | New policy |
| Aug 2, 2026 | Point32Health | Kineret (anakinra) | New policy |
| Aug 2, 2026 | Point32Health | Kevzara (sarilumab) | New policy |
| Aug 2, 2026 | Point32Health | Keveyis (dichlorphenamide) | New policy |
| Aug 2, 2026 | Point32Health | Kerendia (finerenone) | New policy |
| Aug 2, 2026 | Point32Health | Kerendia (finerenone) | New policy |
| Aug 2, 2026 | Point32Health | Juxtapid (lomitapide) | New policy |
| Aug 2, 2026 | Point32Health | Joenja (leniolisib) | New policy |
| Aug 2, 2026 | Point32Health | Joenja (leniolisib) | New policy |
| Aug 2, 2026 | Point32Health | Jesduvroq (daprodustat) | New policy |
| Aug 2, 2026 | Point32Health | Jesduvroq (daprodustat) | New policy |
| Aug 2, 2026 | Point32Health | Jascayd (nerandomilast) | New policy |
| Aug 2, 2026 | Point32Health | Isotretinoin | New policy |
| Aug 2, 2026 | Point32Health | Iron Chelating Agents | New policy |
| Aug 2, 2026 | Point32Health | Intrarosa (prasterone) | New policy |
| Aug 2, 2026 | Point32Health | Insulin-Incretin Mimetic Combinations | New policy |
| Aug 2, 2026 | Point32Health | Insulin and Diabetes Supplies | New policy |
| Aug 2, 2026 | Point32Health | Ingrezza (valbenazine) | New policy |
| Aug 2, 2026 | Point32Health | Incretin Mimetics | New policy |
| Aug 2, 2026 | Point32Health | Increlex (mecasermin) | New policy |
| Aug 2, 2026 | Point32Health | Increlex (mecasermin) | New policy |
| Aug 2, 2026 | Point32Health | Inbrija (levodopa) | New policy |
| Aug 2, 2026 | Point32Health | Impetigo Medications | New policy |
| Aug 2, 2026 | Point32Health | Immunomodulators, Topical | New policy |
| Aug 2, 2026 | Point32Health | Imcivree (setmelanotide) | New policy |
| Aug 2, 2026 | Point32Health | Imcivree (setmelanotide) | New policy |
| Aug 2, 2026 | Point32Health | Ileal Bile Acid Transporter (IBAT) Inhibitors | New policy |
| Aug 2, 2026 | Point32Health | Hypnotic Agents | New policy |